OncoMatch/Clinical Trials/NCT06692166
A Study to Evaluate 9MW2821 Versus Treatment of Physician's Choice for Subjects With Recurrent or Metastatic Cervical Cancer
Is NCT06692166 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments including 9MW2821 and Chemotherapy for cervical cancer.
Treatment: 9MW2821 · Chemotherapy — The purpose of this study is to compare the efficacy and safety of 9MW2821 and chemotherapy in participants with recurrent or metastatic cervical cancer who progressed on or after platinum-based chemotherapy.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Cervical Cancer
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: platinum-based chemotherapy
Subject must have received a platinum-based chemotherapy with or without bevacizumab and received no more than 2 prior systemic therapy in the metastatic/recurrent setting. Subject must have experienced radiographic progression during or after the last treatment regimen.
Cannot have received: nectin-4 targeted antibody-drug conjugate
received treatment of nectin-4 targeted ADC
Cannot have received: antibody-drug conjugate with MMAE payload
received treatment of ADC with MMAE payload
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06692166 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior nectin-4 targeted antibody-drug conjugate, antibody-drug conjugate with MMAE payload disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages